Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) Histological or cytologically confirmed solid tumor malignancy that is locally advanced or metastatic
    2. 2) Progression on or after at least one prior standard of care (SOC) therapy including immune checkpoint inhibitors and therapies targeting known molecular alterations (eg, EGFR, ALK, ROS-1, BRAF, RET, MET, KRAS, MSI-high (MSI-H+)/ddMR, and TMB-H) must have progressed on targeted therapy or be intolerant to standard treatments, or for whom other standard of care treatments may not be appropriate as determined by the treating physician
    3. 3) Patients with a life expectancy of more than 3 months

You may not be eligible for this study if the following are true:

    1. 1) Less than 28 days from prior SOC or other treatment with a biologic
    2. 2) Less than 28 days or 5×half-lives, whichever is longer, from investigational therapy
    3. 3) Less than 28 days from major surgical procedures



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.